Aldeyra Therapeutics (ALDX) Non Operating Income (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Non Operating Income of $94299.0 for Q1 2026, down 54.31% on a QoQ basis from $206376.0 in Q4 2025, and down 81.06% year-over-year from $497958.0 in Q1 2025.
Aldeyra Therapeutics (ALDX) Non Operating Income (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Non Operating Income history runs 14 years deep, the most recent figure standing at $94299.0 for Q1 2026.
- Quarterly Non Operating Income fell 81.06% year-over-year to $94299.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 70.6% YoY) and the FY2025 annual result came in at $1.4 million, down 66.74% from the prior year.
- Non Operating Income was $94299.0 for Q1 2026 at Aldeyra Therapeutics, down from $206376.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.4 million in Q3 2023 and bottomed at -$304585.0 in Q1 2022.
- A 5-year average of $687373.9 and a median of $769017.0 in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 2153.5% — and 2026, when it plunged 81.06%.
- Aldeyra Therapeutics' Non Operating Income stood at $794629.0 in 2022, then surged by 69.24% to $1.3 million in 2023, then slumped by 42.82% to $769017.0 in 2024, then tumbled by 73.16% to $206376.0 in 2025, then slumped by 54.31% to $94299.0 in 2026.
- Business Quant data shows ALDX's Non Operating Income at $94299.0 in Q1 2026, $206376.0 in Q4 2025, and $312791.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Aldeyra Therapeutics | 93.19 Mn | 93.19 Mn | - | 94,299.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94,299.00 |
| Dec 31, 2025 | 206,376.00 |
| Sep 30, 2025 | 312,791.00 |
| Jun 30, 2025 | 401,420.00 |
| Mar 31, 2025 | 497,958.00 |
| Dec 31, 2024 | 769,017.00 |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.34 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.19 Mn |
| Dec 31, 2022 | 794,629.00 |
| Sep 30, 2022 | 231,325.00 |
| Jun 30, 2022 | -66,017.00 |
| Mar 31, 2022 | -304,585.00 |
| Dec 31, 2021 | -350,304.00 |
| Sep 30, 2021 | -353,804.00 |
| Jun 30, 2021 | -393,812.00 |